Stay updated on Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Sign up to get notified when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.

Latest updates to the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.5.3 is now displayed, replacing Revision: v3.5.2 on the page. This indicates a software update to the underlying component, with no changes to study content.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedAdded a new revision tag 'Revision: v3.5.2' and removed the older tag 'Revision: v3.5.0'.SummaryDifference0.1%

- Check40 days agoChange DetectedAdded a new publication to the Publications section: Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 2024 Nov;25(11):1465-1475.SummaryDifference0.1%

- Check55 days agoChange DetectedHepatocellular carcinoma has been added as the condition and the Genetic and Rare Diseases Information Center has been added to the resources. The page revision has been updated to v3.5.0 (replacing v3.4.3).SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check90 days agoChange DetectedAdded a new revision tag (Revision: v3.4.2). Removed an operational status notice about government funding, while the study details and status remain unchanged.SummaryDifference0.4%

Stay in the know with updates to Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Ipilimumab and Nivolumab in Liver Resection Clinical Trial page.